Equities research analysts expect Scpharmaceuticals Inc (NASDAQ:SCPH) to announce earnings per share (EPS) of ($0.59) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Scpharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.61). Scpharmaceuticals posted earnings per share of ($0.47) during the same quarter last year, which indicates a negative year over year growth rate of 25.5%. The firm is scheduled to issue its next earnings results on Monday, May 6th.
According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.07) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.91). For the next fiscal year, analysts expect that the firm will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.46) to ($1.32). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.17.
Several equities analysts recently commented on the company. Zacks Investment Research raised Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday. Svb Leerink cut shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 30th. Finally, Leerink Swann cut shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $12.00 to $5.00 in a research note on Wednesday, January 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $8.50.
SCPH traded up $0.22 during trading hours on Tuesday, reaching $2.70. The company’s stock had a trading volume of 4,900 shares, compared to its average volume of 50,170. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.77 and a current ratio of 13.77. Scpharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $15.70. The stock has a market capitalization of $49.24 million, a PE ratio of -1.70 and a beta of 1.18.
In other news, major shareholder Ra Capital Healthcare Fund Lp acquired 389,862 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average cost of $2.70 per share, with a total value of $1,052,627.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.80% of the stock is owned by insiders.
An institutional investor recently raised its position in Scpharmaceuticals stock. JPMorgan Chase & Co. increased its position in shares of Scpharmaceuticals Inc (NASDAQ:SCPH) by 1,268.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,664 shares of the company’s stock after buying an additional 21,008 shares during the period. JPMorgan Chase & Co. owned 0.12% of Scpharmaceuticals worth $133,000 as of its most recent filing with the Securities and Exchange Commission. 42.24% of the stock is owned by institutional investors and hedge funds.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Further Reading: How to Use the New Google Finance Tool
Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com